Recent Company News

• 07:05 AM ET Apr 29, 2025
  

  EDAP announces results from the FARP randomized controlled trial presented at the AUA annual meeting ($2.18, 0.00)

• 05:44 AM ET Apr 04, 2025
  

  EDAP TMS downgraded to hold from buy at Jefferies (3-April) ($1.91, 0.00)

• 09:16 AM ET Mar 27, 2025
  

  StreetAccount Summary - US Pre-market trading update

• 08:27 AM ET Mar 27, 2025
  

  StreetAccount Summary - US Pre-market trading

• 07:15 AM ET Mar 27, 2025
  

  EDAP TMS reports Q4 EPS (€0.05) vs FactSet (€0.10) [3 est, (€0.11)-(0.09)] ($2.05, 0.00)

• 07:24 AM ET Jan 13, 2025
  

  EDAP reports preliminary Q4 sales of 11 Focal One Systems ($2.10, 0.00)

• 07:12 AM ET Jan 08, 2025
  

  EDAP announced that the first patient has been treated in a phase I/II PULS Trial evaluating HIFU technology for the treatment of pancreatic tumors ($2.55, 0.00)

• 09:13 AM ET Dec 04, 2024
  

  EDAP TMS announces publication of full results from HIFI study in peer-reviewed journal European Urology ($2.47, 0.00)

• 07:08 AM ET Nov 07, 2024
  

  EDAP TMS reports Q3 EPS (€0.17) vs FactSet (€0.15) [3 est, (€0.17)-(0.12)] ($2.84, 0.00)

• 07:06 AM ET Oct 01, 2024
  

  EDAP announces first patients treated in Phase I/II study evaluating focal one robotic HIFU for the treatment of benign prostatic hyperplasia (BPH) ($2.55, 0.00)